US · AORT · MEDICAL - DEVICES
Artivion, Inc. (AORT) intrinsic value and stock valuation
$18.16as of 2026-11-21 · Mkt cap 1.27B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Artivion, Inc. DCF and intrinsic value
InvestorsCraft values AORT with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from AORT’s statements →
Artivion, Inc. Graham Number
Graham Number: $6.92d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Liquidia Corporation (LQDA) $54.43
- Cogent Biosciences, Inc. (COGT) $26.72
- Integer Holdings Corporation (ITGR) $126.97
- LifeStance Health Group, Inc. (LFST) $13.82
- Brookdale Senior Living Inc. (BKD) $8.86
- Addus HomeCare Corporation (ADUS) $122.50
- Inspire Medical Systems, Inc. (INSP) $55.10
- Ardent Health Inc. (ARDT) $15.08
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $441.3M | $388.5M | $354M | $313.8M | $298.8M |
| Operating income | $26.8M | $38.9M | $5.74M | $6.2M | $8.12M |
| Net income | $9.77M | -$-13.36M | -$-30.69M | -$-19.19M | -$-14.83M |
| EPSd | $207.2K | -$-320.54K | -$-753.31K | -$-479.39K | -$-380.45K |
| Operating cash flow | $38.1M | $22.2M | $18.8M | -$-5.15M | -$-2.58M |
| Capital expenditure | -$-39.04M | -$-11.19M | -$-7.43M | -$-10.71M | -$-13.09M |
| Free cash flow | -$-910K | $11.1M | $11.4M | -$-15.87M | -$-15.68M |
| Total assets | $884.8M | $789.1M | $792.4M | $762.8M | $793.1M |
| Total debt | $292M | $362.3M | $358.3M | $356.8M | $362M |
| Net debt | $227.1M | $308.8M | $299.4M | $317.5M | $307M |
| Total equity | $448.2M | $276.2M | $281.8M | $284.3M | $300.7M |
| Cash and short-term investments | $64.9M | $53.5M | $58.9M | $39.4M | $55M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $441.3M | $388.5M | $354M | $313.8M | $298.8M |
| Cost of revenue | $170.9M | $139.8M | $124.8M | $111.3M | $101.3M |
| Gross profit | $270.5M | $248.8M | $229.2M | $202.5M | $197.5M |
| Research and development expenses | $31M | $28.5M | $28.7M | $38.9M | $35.6M |
| Selling, general and administrative expenses | $212.7M | $192.4M | $209M | $157.4M | $169.8M |
| Other expenses | $0.00 | -$-10.92M | -$-14.25M | $0.00 | -$-15.92M |
| Operating expenses | $243.7M | $209.9M | $223.4M | $196.3M | $189.4M |
| Cost and expenses | $414.6M | $349.7M | $348.3M | $307.6M | $290.7M |
| Interest income | $760K | $1.47M | $1.08M | $150K | $80K |
| Interest expense | $26.6M | $34.3M | $25.3M | $18.2M | $16.9M |
| Depreciation and amortization | $22.5M | $24.2M | $23.1M | $22.4M | $24M |
| Ebitda | $63.8M | $51M | $26.8M | $25.7M | $26M |
| Operating income | $26.8M | $38.9M | $5.74M | $6.2M | $8.12M |
| Total other income/expenses, net | -$-11.96M | -$-46.39M | -$-27.33M | -$-21.18M | -$-22.94M |
| Income before tax | $14.8M | -$-7.51M | -$-21.59M | -$-14.98M | -$-14.83M |
| Income tax expense | $5.01M | $5.84M | $9.1M | $4.21M | $10K |
| Net income | $9.77M | -$-13.36M | -$-30.69M | -$-19.19M | -$-14.83M |
| Weighted average shares outstanding | $45.3M | $41.7M | $40.7M | $40M | $39M |
| Weighted average diluted shares outstanding | $47.2M | $41.7M | $40.7M | $40M | $39M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $64.9M | $53.5M | $58.9M | $39.4M | $55M |
| Net receivables | $103.7M | $85.9M | $74.1M | $69.6M | $58.1M |
| Inventory | $92.4M | $79.8M | $82M | $74.5M | $77M |
| Total current assets | $303.6M | $290.1M | $280.7M | $247.3M | $247.7M |
| Property, plant and equipment, net | $99.7M | $76.1M | $82.2M | $80.5M | $83.2M |
| Goodwill and intangible assets | $410.6M | $397.3M | $419.6M | $426.3M | $451.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $581.3M | $499M | $511.7M | $515.5M | $545.4M |
| Total assets | $884.8M | $789.1M | $792.4M | $762.8M | $793.1M |
| Accounts payable | $16M | $18M | $13.3M | $12M | $10.4M |
| Short-term debt | $5.38M | $5.29M | $5.43M | $5.43M | $5.31M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $101.6M | $66.8M | $57.9M | $49.7M | $45M |
| Long-term debt | $286.7M | $357M | $352.9M | $351.4M | $356.7M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $335M | $446.1M | $452.8M | $428.8M | $447.4M |
| Capital lease obligations | $37.1M | $47.9M | $51.4M | $48.7M | $52.9M |
| Total liabilities | $436.6M | $512.9M | $510.6M | $478.5M | $492.3M |
| Common stock | $490K | $430K | $430K | $420K | $410K |
| Retained earnings | -$-51.5M | -$-61.27M | -$-47.91M | -$-17.22M | $1.98M |
| Accumulated other comprehensive income (loss) | -$-2.72M | -$-24.93M | -$-12.01M | -$-21.61M | -$-9.89M |
| Total equity | $448.2M | $276.2M | $281.8M | $284.3M | $300.7M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $292M | $362.3M | $358.3M | $356.8M | $362M |
| Net debt | $227.1M | $308.8M | $299.4M | $317.5M | $307M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $9.77M | -$-13.36M | -$-30.69M | -$-19.19M | -$-14.83M |
| Depreciation and amortization | $22.5M | $24.2M | $23.1M | $22.4M | $24M |
| Stock-based compensation | $24.4M | $14.2M | $14.4M | $12.3M | $10.7M |
| Change in working capital | -$-22.16M | -$-17.24M | -$-16.19M | -$-25.94M | -$-33.23M |
| Accounts receivable | -$-7.27M | -$-15.39M | -$-4.05M | -$-13.34M | -$-11.56M |
| Inventory | -$-15.28M | -$-6.14M | -$-14.36M | -$-8.4M | -$-18.38M |
| Accounts payable | $2.18M | $9.5M | $1.68M | -$-1.96M | -$-1.89M |
| Net cash provided by operating activities | $38.1M | $22.2M | $18.8M | -$-5.15M | -$-2.58M |
| Investments in property, plant and equipment | -$-39.04M | -$-11.19M | -$-7.43M | -$-10.71M | -$-13.09M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-42.04M | -$-28.19M | -$-500K | -$-10.71M | $5.66M |
| Common stock issued | $13.1M | $5.73M | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | -$-560K | -$-1.79M | -$-1.91M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $13M | $2.2M | $860K | -$-1.64M | -$-12.22M |
| Net change in cash | $11.5M | -$-5.48M | $19.6M | -$-15.66M | -$-6.95M |
| Cash at end of period | $64.9M | $53.5M | $58.9M | $39.4M | $55M |
| Operating cash flow | $38.1M | $22.2M | $18.8M | -$-5.15M | -$-2.58M |
| Capital expenditure | -$-39.04M | -$-11.19M | -$-7.43M | -$-10.71M | -$-13.09M |
| Free cash flow | -$-910K | $11.1M | $11.4M | -$-15.87M | -$-15.68M |
Line items
Line items
Line items
About Artivion, Inc.
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
- CEO
- James Patrick Mackin
- Employees
- 1.8K
- Beta
- 1.25
Explore
Frequently asked questions
What is the intrinsic value of Artivion, Inc. (AORT)?
Artivion, Inc. (AORT) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AORT undervalued?
AORT trades at a price of $18.16 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.